Vanda Pharmaceuticals ( VNDA )

Share Interview Share Compensation

$96M Part D

Peak14.5yr

Flagship revenue driver generating ~46% of total revenue; melatonin receptor agonist with 15-year exclusivity runway.

Help build intelligence for Vanda Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established public company with 17-year patent runway on lead asset (HETLIOZ LOE 2041), providing long-term strategic visibility.
Diversified pipeline across 20 active programs spanning Phase 1–4, with multiple Phase 3 catalysts in sleep disorders and rare disease (VCA-894A in CMT received pediatric rare-disease designation July 2026).
40% R&D intensity and $77M annual R&D spend signals serious commitment to pipeline advancement in neurology and niche indications.

Watch Out For

Revenue declined 24% YoY ($254M FY 2024 → $193M FY 2025), signaling market headwinds or product mix erosion that may pressure hiring and bonuses.
Currently zero open job postings and no disclosed hiring by department, suggesting minimal near-term hiring despite active pipeline—potential structural underinvestment in execution capacity.
Heavy dependence on tasimelteon-based products (HETLIOZ + variants account for ~47% of revenue) creates vulnerability to generic competition and regulatory setbacks.

Generated by Claude from Vanda Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

FANAPT

$93M Part D

Peak5.4yr

Second-largest revenue contributor; atypical antipsychotic with dopamine D2/5-HT2 antagonism and active metabolite P88.

PONVORY

Multiple Sclerosis

$8M Part D

Peak16.2yr

Sphingosine 1-phosphate receptor modulator with 16-year exclusivity; modest but growing revenue suggests recent label expansion or market penetration.

TASIMELTEON

$5M Part D

Post-LOE

ANDA generic tasimelteon; post-LOE erosion from brand reflects competitive generic entry in melatonin space.

TASIMELTEON

$5M Part D

Post-LOE

Duplicate ANDA generic tasimelteon entry; post-LOE erosion from brand reflects competitive generic entry in melatonin space.

HETLIOZ LQ

$843K Part D

Peak14.5yr

Liquid formulation of tasimelteon; niche formulation with modest revenue indicating pediatric or compliance-focused label positioning.

NEREUS

Motion Sickness

Launch10.0yr

Recently launched neurokinin-1 antagonist; early-stage revenue ramp with 10-year exclusivity runway; represents pipeline-to-market transition.

ILOPERIDONE

Post-LOE

Post-LOE ANDA generic; contributes to FANAPT erosion as patent exclusivity expires.

ILOPERIDONE

Pre-Launch

Pre-launch ANDA generic; imminent entry will accelerate FANAPT decline post-2031 LOE.

ILOPERIDONE

Sleep-wake Disorder in Blind Individuals

Post-LOE

Post-LOE ANDA generic; duplicate entry reflecting competitive generic market maturity.

Pipeline & Clinical Trials

WGS Analysis of COVID-19 Positive Patients

Coronavirus Infection

N/A

Clinical Trials (1)

NCT04353401WGS Analysis of COVID-19 Positive Patients

N/A

Data collection on blindness and sleep problems

N/A

Clinical Trials (1)

NCT01195558Patient Registry of Blind Subjects With Sleep-related Problems

N/A

Tradipitant

Gastroparesis

N/A

Clinical Trials (1)

NCT04474990Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

N/A

Data collection of sleep disturbances in individuals with SMS

Sleep Disturbances in Smith-Magenis Syndrome

N/A

Clinical Trials (1)

NCT03154697Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

N/A

Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With

Smith Magenis Syndrome

N/A

Clinical Trials (1)

NCT02180451Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)

N/A

Transmeridian travel across multiple time zones

Jet Lag Disorder

N/A

Clinical Trials (1)

NCT02560103An Observational Study to Investigate the Effects of Rapid Transmeridian Travel

N/A

Trichostatin A

Relapsed or Refractory Hematologic Malignancies

PHASE_1

Clinical Trials (1)

NCT03838926Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Phase 1

Iloperidone

Bipolar I Disorder

PHASE_1

Clinical Trials (1)

NCT04127058Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Phase 1

tradipitant

PHASE_1

Clinical Trials (1)

NCT02621385Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects

Phase 1

VHX-896 and iloperidone

PHASE_1

Clinical Trials (1)

NCT04969211Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers

Phase 1

Tasimelteon

PHASE_1

Clinical Trials (1)

NCT06323655Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

Phase 1

VLY-686

Pruritus

PHASE_1

Clinical Trials (1)

NCT01919944Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P

Phase 1

VHX-896

PHASE_1

Clinical Trials (1)

NCT06803290Food Effect Study of VHX-896 in Healthy Volunteers

Phase 1

Tasimelteon Oral Capsule

Safety and Tolerability of Iloperidone

PHASE_1

Clinical Trials (1)

NCT05572281Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Phase 1

iloperidone

PHASE_1

Clinical Trials (1)

NCT01495169Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

Phase 1

VHX-896 and iloperidone

PHASE_1

Clinical Trials (1)

NCT06494397Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Phase 1

Tasimelteon

Circadian Rhythm Sleep Disorders

PHASE_1

Clinical Trials (1)

NCT01540500Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

Phase 1

Tasimelteon

REM Behavior Disorder

PHASE_1

Clinical Trials (1)

NCT05922995The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

Phase 1

tasimelteon

PHASE_1

Clinical Trials (1)

NCT02776215Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

Phase 1

tasimelteon

Hepatic Impairment

PHASE_1

Clinical Trials (1)

NCT01271387Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Phase 1

Iloperidone

Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol

PHASE_1

Clinical Trials (1)

NCT04712734A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Phase 1

tasimelteon

PHASE_1

Clinical Trials (1)

NCT01578057Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol

Phase 1

Tasimelteon

Renal Impairment

PHASE_1

Clinical Trials (1)

NCT01526746Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Phase 1

Tasimelteon

PHASE_1

Clinical Trials (1)

NCT01402076A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

Phase 1

tasimelteon

PHASE_1

Clinical Trials (1)

NCT01637636Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Phase 1

Tasimelteon

Charcot Marie Tooth Disease (CMT)

PHASE_1

Clinical Trials (1)

NCT01477619Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Phase 1

VCA-894A

PHASE_1_2

Clinical Trials (1)

NCT07223632Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

Phase 1/2

Tradipitant

Healthy Volunteer

PHASE_1_2

Clinical Trials (1)

NCT04849559Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Phase 1/2

Iloperidone crystalline formulation